



04-25-02 RECEIVED
1600 MAY 08 2002 9-02
TECH CENTER 1600/2900


EXPRESS MAIL CERTIFICATE
Date 4/23/02 Label No. EV 028721762-45

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

#5

B.W. LEE B.W. Lee
Name (Print) Signature

Customer No.: 
07278
PATENT TRADEMARK OFFICE

Docket No.: 5983/1H567US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mary K. CROW

Serial No.: 10/025,201

Confirmation No.: 5071

Filed: December 19, 2001

For: MARKERS FOR DISEASE SUSCEPTIBILITY AND TARGETS FOR THERAPY

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge the

above deposit account for any deficiency.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: April 23, 2002



Walt Thomas Zielinski
Registration No. 18,902
Attorney for Applicant

DARBY & DARBY
Post Office Box 5257
New York, NY 10150-5257
(212) 527-7700



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

RECEIVED

MAY 07 2002 RECEIVED

TECH CENTER 1600/2900 MAY 10 2002

(REV. 7-80)

TECH CENTER 1600/2900

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 5983/1H567US1
APPLICANT: Mary K. CROW

SERIAL NO: 10/025,201
FILING DATE: December 19, 2001
CONFIRMATION NO: 5071

U.S. PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
-------------------------------	----------------------------	-------------	-------------	--------------	-----------------	--------------------

FOREIGN PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION YES NO</u>
-------------------------------	----------------------------	-------------	----------------	--------------	-----------------	-------------------------------

OTHER REFERENCES**(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)**

*EXAMINER
INITIALS

1. Becker et al., "Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases ", *Proc. Natl. Acad. Sci. USA*, 1998, **95**:9979-9984
2. Gaffney et al., "A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families", *Proc. Natl. Acad. Sci. USA*, 1998, **95**:14875-14879.
3. Kimberland et al., "Full-length human L1 insertions retain the capacity for high frequency retrotransposition in cultured cells", *Human Molecular Genetics*, 1999, **8**:1557-1560.
4. Kolosha et al., "Polymorphic Sequences Encoding the First Open Reading Frame Protein from LINE-1 Ribonucleoprotein Particles (*)", *The American Society for Biochem. And Mol. Biol., Inc.*, 1995, **270**:2868-2873.

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 5983/1H567US1
APPLICANT: Mary K. CROWSERIAL NO: 10/025,201
FILING DATE: December 19, 2001
CONFIRMATION NO: 5071*EXAMINER
INITIALS

5. Leibold et al., "Translation of LINE-1 DNA elements *in vitro* and in human cells", *Proc. Natl. Acad. Sci. USA*, 1990, **87**:6990-6994.
6. Moran et al., "High Frequency Retrotransposition in Cultured Mammalian Cells", *Cell*, 1996, **87**:917-927.
7. Moser et al., "Genome scan of human systemic lupus erythematosus: Evidence for linkage on chromosome 1q in African-American pedigrees", *Proc. Natl. Acad. Sci. USA*, 1998, **95**:14869-14874.
8. Neidhart et al., "Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue", *Arthritis & Rheumatism*, 2000, **43**:2634-2647.
9. Ostertag et al., "Biology of Mammalian L1 Retrotransposons", *Annu. Rev. Genet.*, 2001, **35**:501-538.
10. Risch, "Searching for genetic determinants in the new millennium", *Nature*, 2000, **405**:847-856.
11. Trelogan et al., "Tightly regulated, developmentally specific expression of the first open reading frame from LINE-1 during mouse embryogenesis", *Proc. Natl. Acad. Sci. USA*, 1995, **92**:1520-1524.
12. Woodcock et al., "Asymmetric Methylation in the Hypermethylated CpG Promoter Region of the Human L1 Retrotransposon", *The J. of Biological Chemistry*, 1997, **272**:7810-7816.

EXAMINER: _____

DATE CONSIDERED: _____

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

SHEET 3 OF 3
(REV. 7-80)

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 5983/1H567US1
APPLICANT: Mary K. CROW

SERIAL NO: 10/025,201
FILING DATE: December 19, 2001
CONFIRMATION NO: 5071

* EXAMINER
INITIALS

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.